Trial Profile
A retrospective study to evaluate the efficacy and safety of Alemtuzumab in pediatric heart transplant recipients with refractory rejections
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Jun 2017
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary) ; Diphenhydramine; Methylprednisolone; Paracetamol
- Indications Heart transplant rejection
- Focus Adverse reactions; Therapeutic Use
- 09 Jun 2017 New trial record